MOSCOW (Reuters) – Russia starts a new phase of clinic trials of Russia’s approved COVID-19 vaccine called “Sputnik V” that will involve more than 40,000 people in Moscow, the Russian Direct Investment Fund (RDIF) said on Wednesday.
The RDIF, which is backing the vaccine, said similar trials would be held in five other countries.
The vaccine has been hailed as safe and effective by Russian authorities and scientists following two months of small-scale human trials, the results of which have not been made public yet.
(Reporting by Anastasia Teterevleva and Gabrielle Ttrault-Farber; Writing by Andrey Ostroukh; Editing by Alex Richardson)
